Models for the dispensing of anticancer medications are increasing. As models proliferate, the impact on oncology pharmacy, care delivery, and the patient experience can differ widely. Areas that may be affected include pharmacy operations and management, staffing, workflow, inventory, budget, patient education and monitoring, and more.
As the number of oral anticancer medications continues to grow, so do new challenges for education, delivery, and adherence. Dispensing requirements from manufacturers, payers, and regulators continue to change, as healthcare transitions to a value-based care environment.
Oncology pharmacy professionals, cancer programs and practices, hospitals, and health system pharmacists must stay informed on evolving dispensing models and how to effectively evaluate these for timely, effective, and safe delivery of therapies to patients with cancer.
Evaluating Pharmacy Dispensing Models to Help Improve Cancer Care Delivery
This program seeks to gain deeper insight on the impact variations in dispensing models within hospitals, health systems, or practice groups has on patient-centered cancer care delivery, coordination of care as patients transition between care settings, and optimal pharmacy operations.
Multiple Myeloma Dispensing Models
ACCC is conducting this education program to understand how the current dispensing landscape is affecting delivery of oral therapies for patients with multiple myeloma. To better understand the impact on providers and patients, ACCC is conducting a series of focus group discussions.
Perspectives on Step Therapy in Oncology
This program explores the implications of potential implementation of step therapy in Medicare Advantage plans.
March is Multiple Myeloma Awareness Month. Learn how ACCC is supporting collaboration among healthcare providers with practical, scalable solutions to the real-world challenges of improving quality care delivery for patients with multiple myeloma.
With projects that address acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-Cell ALL, and hematology disease education, ACCC is developing new resources for cancer programs and practices that focus on multidisciplinary approaches to caring for patients with blood cancer.
Insurer mandates requiring patients to have their therapies dispensed via “brown bagging” or “white bagging” are becoming increasingly common. Oncologists treating patients whose insurers require these methods of pharmaceutical procurement have identified problematic issues with them, including concerns about patient safety, proper care coordination, potential treatment delays, and drug waste.
